 |
ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting
Dec 8, 2008
|
10.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 8, 2008--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics using its Tumor-Activated
Prodrug (TAP) technology, today announced the presentation of favorable
clinical fin...
|
|
ImmunoGen, Inc. Announces Genentech's Fifth TAP Technology License
Dec 8, 2008
|
7.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 8, 2008--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Genentech has
licensed the exclusive right to use ImmunoGen's Tumor-Activated Prodrug
(TAP) technology with Genentech...
|
|
ImmunoGen, Inc. Announces Webcast of Panel Session at the RBC Capital Markets 2008 Healthcare Conference
Dec 4, 2008
|
6.4 KB |
| |
WALTHAM, Mass., Dec 04, 2008 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Daniel Junius,
President and Chief Operating Officer, will participate on the panel,
The Power of Collaboration: Genentech and Its Partners, at the RBC
Capital Markets 2008 Healthcare Conference. This 55-minute panel session
...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
Nov 11, 2008
|
6.5 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 11, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that its presentation at the Lazard
Capital Markets 5th Annual Healthcare Conference will be webcast live.
The presentation is scheduled to begin at 1:10 pm EST on November 18,
2008, and will be given at The St. Regis Hotel in New York City. The
pres...
|
|
ImmunoGen, Inc. Appoints James J. O'Leary, MD, as Vice President and Chief Medical Officer
Nov 10, 2008
|
7.5 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 10, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics, today announced that the Company has
appointed James J. O'Leary, MD, as Vice President and Chief Medical
Officer. Dr. O'Leary will lead the clinical development of ImmunoGen's
product candi...
|
|
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
Oct 27, 2008
|
18.4 KB |
| |
WALTHAM, Mass., Oct 27, 2008 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics using its Tumor-Activated
Prodrug (TAP) technology, today announced financial results for the
three-month period ended September 30, 2008 --
the first quarter of t...
|
|
ImmunoGen, Inc. Earns $4 Million Milestone Payment with sanofi-aventis' Initiation of a Phase II Trial with AVE1642
Oct 27, 2008
|
7.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 27, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics, today announced the Company earned a $4
million milestone payment from sanofi-aventis with their initiation of
a Phase II clinical trial with AVE1642.
"Sanofi-aventis is making s...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual BioInvestor Forum
Oct 23, 2008
|
6.2 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its
presentation at the 7th Annual BioInvestor Forum will be webcast live.
The presentation is scheduled to begin at 8:30 a.m. PDT on October 30,
2008, and will be given at the Palace Hotel, San Francisco, CA. The
presentation will provide an update on...
|
|
ImmunoGen, Inc. Announces Bayer HealthCare Has Licensed Rights to TAP Technology for a Solid Tumor Target
Oct 21, 2008
|
7.2 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted anticancer products, today announced that Bayer
HealthCare has licensed exclusive worldwide rights to use ImmunoGen's
Tumor-Activated Prodrug (TAP) technology to develop anticancer
compounds to an undisclosed target found on solid ...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2009 Financial Results
Oct 20, 2008
|
6.5 KB |
| |
WALTHAM, Mass., Oct 20, 2008 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30pm EDT
on Monday, October 27, 2008 to discuss the Company's
financial results for the three-month period ended September 30, 2008 --
the first quarter of ImmunoGen's 2009 fiscal
year. Management also will ...
|
|
ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium
Oct 14, 2008
|
8.3 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics using its Tumor-Activated
Prodrug (TAP) technology, today announced that the posters listed
below, which have ImmunoGen authors, will be presented at the 20th
EORTC-NCI-AACR Symposium on "Molecular Targets ...
|
|
ImmunoGen, Inc. Announces CEO Succession Plan
Sep 30, 2008
|
7.7 KB |
| |
WALTHAM, Mass., Sep 30, 2008 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Daniel M. Junius,
currently President and Chief Operating Officer (COO) of the Company,
will become President and Chief Executive Officer (CEO) effective
January 1, 2009 in accordance with a succession plan approved by
...
|
|
ImmunoGen, Inc. to Present at Upcoming Investor Conferences
Sep 29, 2008
|
6.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN) announced today that the Company
will be presenting at two investor conferences next week. The
presentations will be webcast live by the conference organizers and
can be accessed through the "Investor Information" section of the
ImmunoGen website, http://www.immunogen.com....
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008
Aug 27, 2008
|
6.4 KB |
| |
WALTHAM, Mass., Aug 27, 2008 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at
the Thomas Weisel Partners Healthcare Conference 2008 will be webcast
live. The presentation is scheduled to begin at 11:30a.m. EDT on
September3,2008, and will be given at the Four Seasons Boston hotel.
...
|
|
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology
Aug 12, 2008
|
7.6 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 12, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced that sanofi-aventis has exercised its
option under a 2006 agreement for expanded access to ImmunoGen's
Tumor-Activated Prodrug (TAP) technology.
The exercise of this option enables sanofi-aventis to evaluate,
with certain restrictions, ...
|
|
ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Aug 7, 2008
|
20.4 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 7, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics using its Tumor-Activated Prodrug (TAP)
technology, today announced financial results for the three-month
period and fiscal year ended June 30, 2008.
"The progress being made by us...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2008 Financial Results
Jul 31, 2008
|
6.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--July 31, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN) will host a conference call at 4:30 pm EDT on Thursday,
August 7, 2008 to discuss the Company's financial results for the
three-month period and fiscal year ended June 30, 2008. Management
also will provide an update on the Company.
To access the live cal...
|
|
ImmunoGen, Inc. Announces Senior Management Promotions
Jul 31, 2008
|
8.5 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--July 31, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer products, today announced two senior management promotions.
Daniel M. Junius has been named President and Chief Operating Officer.
John M. Lambert, Ph.D., has been named Executive Vice President,
Research an...
|
|
ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing
Jul 7, 2008
|
8.1 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--July 7, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN) today announced the start of patient dosing in a Phase
I clinical trial evaluating the Company's IMGN388 targeted anticancer
compound for the treatment of solid tumors. IMGN388 uses ImmunoGen's
Tumor-Activated Prodrug (TAP) technology with an antibody that binds
to a...
|
|
ImmunoGen, Inc. Raises $25.0 Million in Registered Direct Offering of Common Stock
Jun 23, 2008
|
7.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--June 23, 2008--ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics, today announced that Ziff Asset Management,
L.P. has purchased approximately 7.8 million shares of ImmunoGen's
common stock at $3.20 per share. The shares were offered by ImmunoGen
pursuant...
|
|
|
